BR0309030A - Métodos para prevenir, tratar ou controlar uma doença ou condição corpórea, para reduzir o colesterol em tecido periférico ao mesmo tempo que reduz ou evita os efeitos adversos associados com a tarapia de lipossoma, para prevenir ou tratar uma doença ou distúrbio associado (a) com os nìveis de colesterol anormais, e para reduzir o colesterol em um ser humano doente - Google Patents

Métodos para prevenir, tratar ou controlar uma doença ou condição corpórea, para reduzir o colesterol em tecido periférico ao mesmo tempo que reduz ou evita os efeitos adversos associados com a tarapia de lipossoma, para prevenir ou tratar uma doença ou distúrbio associado (a) com os nìveis de colesterol anormais, e para reduzir o colesterol em um ser humano doente

Info

Publication number
BR0309030A
BR0309030A BR0309030-2A BR0309030A BR0309030A BR 0309030 A BR0309030 A BR 0309030A BR 0309030 A BR0309030 A BR 0309030A BR 0309030 A BR0309030 A BR 0309030A
Authority
BR
Brazil
Prior art keywords
treat
prevent
disease
cholesterol
methods
Prior art date
Application number
BR0309030-2A
Other languages
English (en)
Inventor
Wendi V Rodriqueza
Charles L Bisgaier
Original Assignee
Esperion Luv Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Luv Dev Inc filed Critical Esperion Luv Dev Inc
Publication of BR0309030A publication Critical patent/BR0309030A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODOS PARA PREVENIR, TRATAR OU CONTROLAR UMA DOENçA OU CONDIçãO CORPóREA, PARA REDUZIR O COLESTEROL EM TECIDO PERIFéRICO AO MESMO TEMPO QUE REDUZ OU EVITA OS EFEITOS ADVERSOS ASSOCIADOS COM A TERAPIA DE LIPOSSOMA, PARA PREVENIR OU TRATAR UMA DOENçA OU DISTúRBIO ASSOCIADO(A) COM OS NìVEIS DE COLESTEROL ANORMAIS, E PARA REDUZIR O COLESTEROL EM UM SER HUMANO DOENTE". A presente invenção diz respeito às formulações farmacêuticas que compreendem lipossomas e aos métodos para usar tais lipossomas para prevenir, tratar ou controlar uma variedade de doenças e/ou condições corpóreas. Os lipossomas podem compreender vesículas unilamelares grandes (LUVs) sozinhas ou em combinação com vesículas multilamelares (MLVs), vesículas unilamelares pequenas (SUVs) ou outros produtos terapêuticos. A invenção diz respeito aos lipossomas tendo certos diâmetros administrados aos pacientes usando doses específicas e/ou regimes de dosagem.
BR0309030-2A 2002-04-05 2003-04-04 Métodos para prevenir, tratar ou controlar uma doença ou condição corpórea, para reduzir o colesterol em tecido periférico ao mesmo tempo que reduz ou evita os efeitos adversos associados com a tarapia de lipossoma, para prevenir ou tratar uma doença ou distúrbio associado (a) com os nìveis de colesterol anormais, e para reduzir o colesterol em um ser humano doente BR0309030A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37040902P 2002-04-05 2002-04-05
PCT/US2003/010339 WO2003086351A1 (en) 2002-04-05 2003-04-04 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease

Publications (1)

Publication Number Publication Date
BR0309030A true BR0309030A (pt) 2005-02-01

Family

ID=29250522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309030-2A BR0309030A (pt) 2002-04-05 2003-04-04 Métodos para prevenir, tratar ou controlar uma doença ou condição corpórea, para reduzir o colesterol em tecido periférico ao mesmo tempo que reduz ou evita os efeitos adversos associados com a tarapia de lipossoma, para prevenir ou tratar uma doença ou distúrbio associado (a) com os nìveis de colesterol anormais, e para reduzir o colesterol em um ser humano doente

Country Status (26)

Country Link
US (2) US20040009216A1 (pt)
EP (1) EP1501482A1 (pt)
JP (1) JP2005527582A (pt)
KR (1) KR20050009988A (pt)
CN (1) CN1655764A (pt)
AP (1) AP2004003157A0 (pt)
AU (1) AU2003230800A1 (pt)
BR (1) BR0309030A (pt)
CA (1) CA2480763A1 (pt)
CR (1) CR7563A (pt)
EA (1) EA007986B1 (pt)
EC (1) ECSP045409A (pt)
HR (1) HRP20040915A2 (pt)
IL (1) IL164370A0 (pt)
IS (1) IS7493A (pt)
MA (1) MA27298A1 (pt)
MX (1) MXPA04009692A (pt)
NO (1) NO20044751L (pt)
NZ (1) NZ535900A (pt)
OA (1) OA12799A (pt)
PL (1) PL372689A1 (pt)
RS (1) RS87704A (pt)
TN (1) TNSN04190A1 (pt)
UA (1) UA80121C2 (pt)
WO (1) WO2003086351A1 (pt)
ZA (1) ZA200407947B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037270A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
AU2003275850A1 (en) * 2002-10-25 2004-05-13 Vasogen Ireland Limited Cyclooxygenase regulation with ps liposomes
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
CN1826123A (zh) * 2003-07-21 2006-08-30 瓦索金爱尔兰有限公司 急性炎症状态的治疗方法
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
US20100166838A1 (en) * 2004-11-23 2010-07-01 Wendy Bollinger Bollag Methods And Compositions For Modulating Keratinocyte Function
KR100891595B1 (ko) * 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
JP4395658B2 (ja) * 2005-11-17 2010-01-13 エムジーファーマ株式会社 コレステロール再上昇抑制用組成物およびその用法
WO2008018932A2 (en) * 2006-05-01 2008-02-14 The Board Of Trustees Of The Leland Stanford Junior University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
CN103614375A (zh) 2006-05-11 2014-03-05 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
AU2009241591A1 (en) * 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of DSRNA targeting the PCSK9 gene
AU2010223967B2 (en) * 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
AU2010255391C1 (en) * 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
HUE056773T2 (hu) * 2009-06-10 2022-03-28 Arbutus Biopharma Corp Továbbfejlesztett lipid készítmény
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
US8273869B2 (en) * 2009-06-15 2012-09-25 Alnylam Pharmaceuticals, Inc. Lipid formulated dsRNA targeting the PCSK9 gene
WO2011059262A2 (ko) * 2009-11-13 2011-05-19 경북대학교 산학협력단 사멸세포 표적 펩타이드, 표지물질 및 치료제를 포함하는 리포솜의 아포토시스 관련 질환의 예방, 치료 또는 치료진단을 위한 용도
KR20140054066A (ko) 2011-07-15 2014-05-08 뉴서트 사이언시스, 인크. 대사 경로 조절을 위한 조성물 및 방법
WO2014078459A1 (en) 2012-11-13 2014-05-22 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN104422750B (zh) * 2013-09-05 2016-02-10 中国科学院大连化学物理研究所 一种烟叶中磷脂酰乙醇胺与甘油三酯含量的检测方法
JP6453245B2 (ja) 2014-01-17 2019-01-16 株式会社 西崎創薬研究所 Ｇｌｕｔ４エンドサイトーシス抑制剤
CN110279654B (zh) * 2019-07-22 2023-02-03 苏州大学附属第一医院 缓释阿司匹林脂质体水凝胶、制备方法及其在制备治疗复发性腰椎间盘突出症药物中的应用
AU2021392472A1 (en) * 2020-12-04 2023-07-06 Osaka University Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics
US11806507B2 (en) 2020-12-22 2023-11-07 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
AU2021409558A1 (en) * 2020-12-22 2023-07-20 Regina E. HERZLINGER Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
JPS5348976A (en) * 1976-10-18 1978-05-02 Nippon Zeon Co Ltd Mass transfer apparatus of hollow fiber type
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4247393A (en) * 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
DE3276390D1 (en) * 1981-09-10 1987-06-25 Intermedicat Gmbh Method for the selective extracorporeal precipitation of low-density lipoproteins from serum or plasma
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4532089A (en) * 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4978654A (en) * 1984-04-16 1990-12-18 Board Of Regents, The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
ATE120640T1 (de) * 1989-04-18 1995-04-15 Vestar Inc Markierung mit liposomen von ischämischen geweben.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DE4018767A1 (de) * 1990-06-12 1991-12-19 Braun Melsungen Ag Wirkstofffreie liposomen zur behandlung von atherosklerose
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
JPH04305879A (ja) * 1990-09-12 1992-10-28 Fuji Electric Co Ltd ディスク記憶装置のヘッド操作用可動体の拘束装置
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
US5250060A (en) * 1992-06-26 1993-10-05 Carbo Paul L Angioplasty apparatus
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6312719B1 (en) * 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US5599306A (en) * 1994-04-01 1997-02-04 Localmed, Inc. Method and apparatus for providing external perfusion lumens on balloon catheters
US5622715A (en) * 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5674488A (en) * 1994-10-07 1997-10-07 Reich; John J. Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
CA2206289A1 (en) * 1994-11-23 1996-05-30 Kimberly-Clark Worldwide, Inc. Absorbent article having a composite absorbent core
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
MXPA98002791A (es) * 1995-10-11 2004-09-07 Esperion Luv Dev Inc Composiciones liposomales y metodos para usarlas.
US5846691A (en) * 1996-07-08 1998-12-08 Polyfibron Technologies, Inc. Composite relief image printing plates and methods for preparing same
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
WO2000059855A1 (en) * 1999-04-01 2000-10-12 Esperion Therapeutics, Inc. Ether compounds, compositions, and uses thereof
JP2003508349A (ja) * 1999-05-14 2003-03-04 エスペリオン エルユーブイ ディベロップメント， インコーポレイテッド アンギナおよび／またはアンギナ等価状態を処置する方法、ならびにそれに関連する薬学的組成物およびキット
PL369545A1 (en) * 2001-09-28 2005-05-02 Esperion Therapeutics, Inc. Methods and apparatus for extrusion of vesicles at high pressure

Also Published As

Publication number Publication date
IL164370A0 (en) 2005-12-18
RS87704A (en) 2006-12-15
US20040009216A1 (en) 2004-01-15
HRP20040915A2 (en) 2005-02-28
ECSP045409A (es) 2005-03-10
NZ535900A (en) 2008-08-29
MA27298A1 (fr) 2005-05-02
IS7493A (is) 2004-10-08
AU2003230800A1 (en) 2003-10-27
UA80121C2 (en) 2007-08-27
KR20050009988A (ko) 2005-01-26
ZA200407947B (en) 2006-07-26
CR7563A (es) 2005-09-20
AP2004003157A0 (en) 2004-12-31
JP2005527582A (ja) 2005-09-15
TNSN04190A1 (en) 2007-03-12
WO2003086351A1 (en) 2003-10-23
CN1655764A (zh) 2005-08-17
NO20044751L (no) 2004-12-20
CA2480763A1 (en) 2003-10-23
EA007986B1 (ru) 2007-02-27
EP1501482A1 (en) 2005-02-02
MXPA04009692A (es) 2006-03-08
EA200401317A1 (ru) 2005-06-30
PL372689A1 (en) 2005-07-25
OA12799A (en) 2006-07-11
US20080213351A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
BR0309030A (pt) Métodos para prevenir, tratar ou controlar uma doença ou condição corpórea, para reduzir o colesterol em tecido periférico ao mesmo tempo que reduz ou evita os efeitos adversos associados com a tarapia de lipossoma, para prevenir ou tratar uma doença ou distúrbio associado (a) com os nìveis de colesterol anormais, e para reduzir o colesterol em um ser humano doente
Lascelles et al. An extended release local anaesthetic: potential for future use in veterinary surgical patients?
ES2191329T3 (es) Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
Bulai Livideanu et al. Efficacy of ustekinumab in palmoplantar psoriasis
Gao et al. Effects of intracerebroventricular application of the delta opioid receptor agonist [D-Ala2, D-Leu5] enkephalin on neurological recovery following asphyxial cardiac arrest in rats
Jaichandran et al. Local anesthetic agents for vitreoretinal surgery: no advantage to mixing solutions
Sandford et al. Amitriptyline and carbamazepine in the treatment of dysesthetic pain in spinal cord injury
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ES2239316T3 (es) Metodo para el tratamiento de la obesidad usando moduladores de prolactina y dieta.
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
WO2022197899A3 (en) Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
Li et al. Therapeutic effect of methylprednisolone combined with high frequency electrotherapy on acute spinal cord injury in rats
KR20080059229A (ko) 정상적 호흡 리듬의 회복을 위한 ｓ-니트로소티올계 조합제약 생성물
Hamawy et al. Rocuronium versus magnesium as an adjuvant to local anesthetics in peribulbar block
NO319421B1 (no) Terapeutisk bruk av melatonin
Ueha et al. Optimization of antitumor treatment conditions for transcutaneous CO2 application: An in vivo study
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
PL367204A1 (en) Use of l-carnitine as stabilizing agent of proteins
Nishiyama et al. The effects of intrathecal morphine encapsulated in L-and D-dipalmitoylphosphatidyl choline liposomes on acute nociception in rats
Weksler et al. Lidocaine pretreatment effectively decreases the incidence of hiccups during methohexitone administration for dilatation and curettage
Lauretti et al. Comparison of botox® or prosigne® and facial nerve blockade as adjuvant in chronic migraine
McCarberg et al. Therapeutic benefits of continuous low-level heat wrap therapy (CLHT) for osteoarthritis (OA) of the knee
Türkyılmaz et al. The effect of preemptive ketamine on postoperative analgesia in lower extremity surgery

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 DA RPI 2116 DE 26/07/2011.